Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
-
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
-
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations
-
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
-
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
The results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM).
-
NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma
Headline results reported in March, demonstrated that the study had achieved its primary endpoint.
-
GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations
More than 30 abstracts from the company will be featured at the meeting.
-
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
-
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
-
GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen
Agreement further strengthens respiratory pipeline of targeted biological therapies
-
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
-
GSK announces significant new investment in UK manufacturing network
GSK today announced £275 million of new investments at three of its manufacturing sites in the UK
-
ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV
ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study
-
GSK and Save the Children call for developing country innovations to enter $1 million award
GSK and Save the Children today launched their fourth annual $1 million Healthcare Innovation Award.
-
Update on GSK’s response to the Zika virus disease outbreak
Since the outbreak of Zika virus disease began in the Americas late last year, GSK has been assessing how we can best help to respond.
-
GSK announces start of phase I oncology study with its ICOS agonist antibody
The start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody
-
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients
FULFIL - Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy
-
Executive Director Change
Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017.
-
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.
-
New Phase III data shows greater treatment response with GSK’s Benlysta® (belimumab) vs placebo in patients with highly active SLE
BLISS-SC builds on an extensive clinical trial programme for belimumab, which is the largest clinical programme in SLE to date.